Previous studies have shown that the pharmacological inhibition of both PLK1 and BIRC5 synergistically compromises the viability of p53-mutated HCC cells in vitro and in vivo by the combination treatment of volasertib with YM155 [103]. Here, TP53 is linked to hepatocellular carcinoma.